| Bioactivity | MT-4 blocks the TG2/FN complex at the interface between cancer cells and the tumor niche. MT-4 inhibits the adhesion of ovarian cancer (OC) cells to the peritoneum[1]. | ||||||||||||
| Target | TG2/FN complex. | ||||||||||||
| Invitro | Pre-treatment with MT4 sensitizes ovarian cancer (OC) cells to traditional anticancer drug[1]. | ||||||||||||
| Name | MT-4 | ||||||||||||
| CAS | 2327925-35-7 | ||||||||||||
| Formula | C21H23N5O | ||||||||||||
| Molar Mass | 361.44 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Sima LE, et al. Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin. Mol Cancer Ther. 2019 Jun;18(6):1057-1068. |